A Look at the Orthocell Share Price: Can It Keep Going Up? 

By ,

At time of writing, the share price of Orthocell Ltd [ASX:OCCis up 2.46%, trading at 62.5 cents per share. 

Despite a recent pullback, it has been an exciting ride for investors with the Orthocell share price going through the roof on 8 May: 

 Orthocell Share Price

Source: marketindex.com.au 

Today we will be looking at what caused Orthocell’s remarkable rise and its prospects going forward. 

Related: Missed the Orthocell train? Download your free report to learn how to invest in lucrative biotech stocks. 

Orthocell share price reacts to nerve regeneration trial

The Orthocell share price spike started with news that four patients had successfully completed a nerve regeneration clinical trial using the company’s CelGro® treatment. 

As the announcement noted: 

Prior to surgery with CelGro®, the first four patients scored a muscle power of zero (0), with complete paralysis or significant difficulties in performing activities of daily living. Following CelGro® nerve regeneration treatment, the first four patients all scored a muscle power of four (4), representing an 83% improvement.  

The very positive results indicate CelGro® can accelerate and augment the repair of damaged or severed nerves. Tensionless repair of peripheral nerves is of significant clinical interest to the orthopaedic community because of the potential improvements in efficiency and efficacy of surgical procedures. Tensionless repair will reduce surgery time and the risk of additional trauma to soft tissue through the use of sutures. 

CelGro® is a collagen medical device platform for soft tissue regeneration and repair applications. 

You can see what this looks like below with regards to soft tissue repair: 

Orthocell Share Price

Source: newswire 

For investors, the most exciting thing about the successful clinical trial is that it has the potential to massively expand Orthocell’s addressable market  that is the revenue opportunity for a product or service. 

In their half-yearly report, Orthocell said that the addressable market for CelGro® was $2.6 billion. 

This has now jumped out another $1.1 billion with the nerve regeneration opportunity. 

Orthocell estimates that approximately 700,000 procedures that could use CelGro® are completed each year. 

The expansion of the uses of CelGro® beyond the dental market can only be seen as good news for the company. 

The company had previously been focusing on dental bone and soft tissue repair. 

What are Orthocell’s prospects?

While the recent pullback may have come as a shock  it is understandable as many long-term holders could be evaluating their position after suffering over the course of the year. 

Going forward, it seems at this juncture the company is now focused on two primary things  marketing and future clinical trials. 

An upcoming announcement of the results of the rest of the ongoing trial could also prove a boon with the company noting that: 

The study involves 20 patients with traumatic nerve injury requiring surgical repair. Orthocell has treated 75% of patients (15 of 20), with recruitment expected to be completed by Q2 CY2019. 

Meanwhile, the dental market in Europe remains a focus and it is seeking regulatory approval for this application in the US and Australia. 

Over the coming weeks, it is possible you may see brief pullbacks as investors cash in on a spectacular rise. 

That being said, this particular biotech stock seems to have a more solid base (and could keep going up at a more subdued pace) than previous biotech darling Biotron Ltd [ASX:BIT]. 

If you are new to the biotech space or need additional pointers on how to pick winners, download this report to learn the intricacies of the market. 


Lachlann Tierney,
For Money Morning 

About Lachlann Tierney

Lachlann Tierney is an Analyst for Money Morning and has been investing for nearly a decade. With a Masters of Science from the London School of Economics, he brings a sound understanding of global markets to his writing. Lachlann is interested in emerging technologies, energy solutions and helping people invest…

Orthocell Share Price Up 25% on FDA Approval (ASX:OCC)

Drug development is a long and tedious process, often taking years to reach commercialisation. Small-cap biotech company Orthocell Ltd [ASX:OCC] knows this all too well, having spent years bringing their tissue repair…

Biotron Share Price Shoots 26% Higher on Preliminary COVID-19 Results

The hunt for a COVID-19 vaccine is ramping up. We learnt yesterday that the government has spent $1.7 billion on potential treatments. Hedging their bets on some $84 million worth of doses that will be ready for free rollouts by 2021…

Three Stocks to Watch during the Coronavirus Rollercoaster

Market volatility is continuing to rise amidst the ongoing global pandemic. Worst yet, it is difficult to pinpoint when this is likely to end. Markets are up one day and crashing down the next. It is a telling sign when investors begin to look for safety among some of Australia’s most speculative small-caps…

Orthocell Pauses Trading in Hopes for More Cash (ASX:OCC)

Small-cap biotech company Orthocell Ltd [ASX:OCC] has entered a trading halt today. A request that will give them time to announce a fresh capital raise. As it stands we are scant for details.

Orthocell Share Price Up 21.5% with More CelGro Results (ASX: OCC)

Aussie biotech Orthocell Ltd [ASX:OCC] has seen a magnificent spike in their share price today, up a whopping 21.5% at time of writing. Results from clinical trials of their core regenerative medical solution CelGro, have led to such spikes in the Orthocell share price throughout 2019, and today is no exception…

Orthocell Share Price Up 11.4% With Clinical Trial Update

Shares of regenerative medicine company Orthocell Ltd [ASX:OCC] have soared in today’s trading, currently up over 11% at time of writing. The biotech small-cap released the final results today of their CelGro clinical trial, which was successfully completed back in May.